THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Long-term mortality and recurrent vascular events in lacunar versus non-lacunar ischaemic stroke

Citation for published version:

Portegijs, S, Ong, AY, Halbesma, N, Hutchinson, A, Sudlow, CLM & Jackson, CA 2021, 'Long-term mortality and recurrent vascular events in lacunar versus non-lacunar ischaemic stroke: a cohort study', *European Stroke Journal*. <https://doi.org/10.1177/23969873211062019>

Digital Object Identifier (DOI):

[10.1177/23969873211062019](https://doi.org/10.1177/23969873211062019)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

European Stroke Journal

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Long-term mortality and recurrent vascular events in lacunar versus non-lacunar ischaemic stroke: a cohort study

Portegijs S (MSc)^{1,2*}, Ong AY (MBChB)^{3*}, Halbesma N (PhD)¹, Hutchinson A (MSc)^{1,4}, Sudlow CLM (DPhil)^{1,4} Jackson CA (PhD)^{1†}

¹Usher Institute, University of Edinburgh, Scotland

²Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

³NHS Lothian, Edinburgh, Scotland

⁴Centre for Clinical Brain Sciences, University of Edinburgh, Scotland

*These authors contributed equally to the manuscript

†Corresponding author:

Usher Institute, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, Scotland

Email: caroline.jackson@ed.ac.uk; tel: +44 (0)131 6503223

Abstract

Introduction Studies ~~of on the~~ differences in very long-term outcomes between people with ~~versus without~~ lacunar/small vessel disease (SVD) ~~versus other types of~~ ischaemic stroke report mixed findings, with limited data on ~~risks of~~ myocardial infarction (MI). We investigated whether long-term mortality, recurrent stroke and MI risks differ in people with versus without lacunar/SVD ischaemic stroke.

Patients and methods We included first-ever strokes from a hospital-based stroke cohort study recruited in 2002-2005. We compared risks of death, recurrent stroke and MI during follow-up among lacunar/SVD versus other ischaemic stroke subtypes using Cox regression, adjusting for confounding factors.

Results We included 812 participants, 283 with lacunar/SVD ischaemic stroke and 529 with other stroke. During ~~a~~ median ~~of~~ 9.2 years (interquartile range 3.1-11.8), there were 519 deaths, 181 recurrent strokes and 79 MIs. Lacunar/SVD stroke was associated with lower mortality (adjusted HR 0.79, 95% CI 0.65 to 0.95), largely due to marked~~ly~~ lower all-cause mortality in the first year. From one year onwards this difference attenuated, with all-cause mortality only slightly ~~and not statistically significantly~~ lower ~~in among~~ the lacunar/SVD group, ~~although not quite statistically significant~~ (0.86, 95% CI 0.70 to 1.05). There was no clear difference in risk of recurrent stroke (HR 0.84, 95% CI 0.61-1.15) or MI (HR 0.83, 95% CI 0.52-1.34).

Conclusion Long-term risks of all-cause mortality, recurrent stroke and MI ~~are may be~~ similar, or only slightly lower, in patients with lacunar/SVD as compared to other ischaemic stroke. ~~Patients and~~ physicians should be as vigilant in optimising short and long-term secondary prevention of vascular events in lacunar/SVD as for other stroke types.

Keywords: Ischaemic stroke; lacunar stroke; small vessel disease; mortality; recurrent stroke; myocardial infarction

INTRODUCTION

In high-income settings, ischaemic strokes comprise about 85% of all strokes, around 25% of which are ‘lacunar’ strokes, attributed to small vessel disease (SVD) affecting the deep penetrating arterioles of the brain.^{1,2} Until relatively recently, compared with other stroke subtypes, lacunar/SVD strokes were considered to be relatively benign, due to lower stroke severity at initial presentation and lower early case fatality.^{3,4} However, lacunar/SVD strokes are now recognised to have substantial long-term consequences, including physical and cognitive decline.^{3,5}

In a previous systematic review and meta-analysis, we found lower risks of death and recurrent stroke in the first month after lacunar/SVD versus other ischaemic stroke subtypes, with attenuation of these differences thereafter.⁶ However, very few studies reported on long-term outcomes, comparisons of recurrent stroke risk beyond one month were limited by low precision and risk of myocardial infarction (MI) among ischaemic stroke subtypes had rarely been investigated. Our own hospital-based stroke cohort study, with follow-up for up to four years, subsequently reported a lower early risk of recurrent stroke among people with lacunar/SVD versus other ischaemic stroke subtypes, and a trend towards a reduced risk of MI among those with lacunar/SVD stroke (but based on small numbers of MI).⁷ Over the last decade, more studies have reported on outcomes among different ischaemic stroke subtype groups over a longer follow-up period (exceeding five years), but findings appear somewhat mixed and data on risks of MI remain scarce.⁸⁻¹²

Differences in long-term prognosis for vascular events following different subtypes of ischaemic stroke may have important implications for clinical management, particularly vascular secondary prevention. In the present study, we extended the follow-up of our hospital-based stroke cohort for up to 14 years through individual level linkages to Scotland’s national hospital admission and mortality databases, to compare long-term risks of death, recurrent stroke and MI among people with lacunar/SVD versus other ischaemic stroke subtypes.

PATIENTS AND METHODS

This article is presented in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. The study was approved by the relevant regional Research Ethics Committee (LREC 2001/4/46) and the Scottish National Health Service (NHS) Public Benefit and Privacy Panel provided approval for data linkage.

Setting and study population

We included participants recruited to the Edinburgh Stroke Study (ESS), a prospective cohort of consecutive [consenting](#) adult patients with [ischaemic or haemorrhagic](#) stroke (defined according to the classical WHO criteria¹³), admitted as inpatients or referred by primary care physicians to the stroke/transient ischaemic attack outpatient clinic at a large university hospital from 2002-2005. At recruitment we collected information on stroke onset, symptoms and signs, clinical risk factors, premorbid functional status, lifestyle factors and results of clinical investigations. We obtained informed consent, including for long-term follow-up through linkage to national health records, from all recruited patients, or from relatives (or where necessary through waiver of consent) when patients were unable to provide consent.

For the present study, we linked our original cohort to all Scottish general hospital inpatient records and national death records and included patients with a first-ever ischaemic stroke aged 40 years or more at recruitment.

Ischaemic stroke subtype classification

We categorised ischaemic stroke subtypes according to an anatomical classification based on clinical and brain imaging features. We used the Oxfordshire Community Stroke Project (OCSP) classification to assign a clinical syndrome indicating the presumed site and size of the causative infarct using the clinical features of the stroke which was then modified if necessary by the findings on brain imaging if an infarct considered relevant to the presenting stroke was present (Figure 1; Supplementary Table 1).

To allow comparisons with studies that used a mechanistic ischaemic stroke classification, we retrospectively applied a modified Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification¹⁴ to create ischaemic stroke subtype groups based on presumed stroke mechanism (Supplementary Table 1). In secondary analyses we compared SVD versus large vessel disease (LVD) or cardioembolic (CE) stroke.

Follow-up and outcome definitions

During the original study we used a 'hot pursuit' method to prospectively follow patients for one to four years post-stroke for death, recurrent stroke and MI. These methods included multiple overlapping sources, including alerts from clinical colleagues, patient questionnaires, contact with general practitioners and death certificates. Whenever possible, we arranged for specialist review and investigation of patients with a suspected recurrent stroke. For patients with suspected MI, and those unable to attend a clinical assessment for suspected recurrent stroke, we confirmed or refuted events through review of paper and electronic medical records. In the present

study, we ascertained recurrent stroke during the first year post-stroke solely from the prospective hot pursuit methods (defining recurrent stroke using the same WHO definition as for index stroke and requiring a period of neurological stability of 24 hours between index and recurrent stroke, and exclusion of other potential causes of neurological deterioration). Relying on linkages to coded hospital admission data to identify recurrences during this period, when recurrence risk is highest, would have underestimated early recurrence risk. From one-year post-stroke onwards we identified recurrent strokes from [linked-linkage, via a unique community health index number, to](#) hospital admission and mortality records. To optimise the accurate identification of clinically symptomatic strokes fulfilling the WHO definition and occurring beyond one-year of the index stroke, we used stroke-specific ICD-10 codes (i.e., I60, I61, I63 and I64), appearing in the primary or secondary hospital diagnosis or cause of death data fields.¹⁵

We ascertained MI events during the whole period from hospital admission or mortality records which indicated an acute MI (ICD-10 I21) in the primary or secondary position and from the 'hot pursuit' prospective follow-up phase of the ESS (where MI was defined as either autopsy evidence or at least two of the following: symptoms of myocardial ischemia [e.g. chest pain]; enzyme changes indicative of MI [generally an acute rise in troponin level]; and ECG changes suggesting new ischemia [new ST-T wave changes, Q waves, or left bundle branch block] or sudden death without evidence of an alternative cause).

We identified all-cause mortality through linkage to coded, national mortality records.

Statistical analysis

We performed statistical analyses using SPSS version 22 (IBM, New York, USA) and Stata version 14. We compared baseline characteristics using the χ^2 test for categorical variables, Student's t-test for continuous variables and tests for differences for non-normally distributed variables. For each outcome, we used Kaplan-Meier survival analysis to obtain 1-year, 5-year and 10-year cumulative incidence with 95% confidence intervals (CIs) for lacunar/SVD and other ischaemic subtype groups. We compared people with lacunar/SVD versus other ischaemic strokes, using Cox regression analysis to obtain age- and sex- adjusted and additionally adjusted hazard ratios (HRs) with 95% CIs for each outcome, for the entire follow-up time, 0-1 year and one year to end of follow-up. [In the models for mortality and recurrent stroke we adjusted for age, sex, history of ischaemic heart disease, atrial fibrillation, cardiac failure and smoking status. In the analysis of MI, we adjusted for age, sex, history of ischaemic heart disease, atrial fibrillation and smoking.](#) We followed patients from stroke date to date of

outcome, death or end of follow-up (31 Dec 2015). Information on one or more covariates was missing in only 12 patients and so we performed a complete-case analysis. We checked models for violation of the proportional hazard assumption using log minus log plots and plotting the Schoenfeld residuals.

We performed sensitivity analyses where we calculated sub-distribution HRs for recurrent stroke and MI (treating death as a competing risk). Since stroke severity was not documented for the majority of patients, we repeated the analyses for each outcome stratifying by inpatient/outpatient status at recruitment, as a proxy for more versus less severe strokes. [We also performed a sensitivity analysis where we repeated the analyses having excluded patients who died within the first three months of the stroke event.](#)

RESULTS

We included 812 patients with first-ever ischaemic stroke (283 lacunar/SVD, 529 other ischaemic; Figure 1), followed up for a maximum of 14 years (median 9.2, IQR 3.1-11.8). Of these 812 patients, 509 had a visible relevant infarct on their scan, 64 (13%) of whom were allocated to a different comparison group (i.e. lacunar/SVD or other ischaemic stroke type) than would have been the case based on their clinical syndrome alone, with lacunar and non-lacunar strokes equally misclassified. Applying this to the number with no visible infarct, we estimate that 6% of participants were residually misclassified between comparison groups. The inclusion of a slightly higher proportion of lacunar patients (35%) than might be expected reflects the inclusion of (i) milder strokes recruited from an outpatient clinic servicing the whole city and (ii) inpatients from one of three city hospitals receiving acute stroke patients. Patients with lacunar/SVD stroke were slightly (but not significantly) younger than patients with other ischaemic stroke subtypes and more often male and current smokers. Atrial fibrillation, severe ipsilateral carotid stenosis and previous history of ischaemic heart disease were significantly less common in patients with lacunar/SVD versus other ischaemic stroke (Table 1).

During follow-up, 159 and 360 deaths occurred among patients with lacunar/SVD and other ischaemic stroke, respectively. During the first year, cumulative mortality was lower among people with lacunar/SVD than other ischaemic stroke. This difference persisted at 5 years and 10 years, but attenuated between 5 and 10 years (Figure 2a and Table 2). In adjusted analyses, people with lacunar/SVD stroke had lower mortality risk than other ischaemic stroke subtypes over the entire follow-up period (adjusted HR lacunar/SVD vs others: 0.79, 95% CI 0.65 to 0.95; $p = 0.015$), largely explained by a much lower risk of dying after lacunar/SVD stroke in the first year (0-1 year HR 0.49, 95% CI 0.28 to 0.84). From one year onwards the difference in risk attenuated, suggesting only a

slightly lower mortality risk among the lacunar/SVD group, although this did not reach statistical significance (0.86, 95% CI 0.70 to 1.05; Table 3). [When we excluded patients who died within three months of the stroke, we found that, among 766 remaining patients, those with a lacunar/SVD stroke had an 18% lower mortality risk than other ischaemic stroke \(adjusted HR 0.82, 95% CI 0.67 to 1.00, p=0.045\).](#)

During the entire follow-up period, [59 and 122](#) ~~and 59~~ recurrent strokes occurred among patients with lacunar/SVD and other ischaemic stroke, respectively. At 1, 5 and 10 years, there was little difference in the cumulative incidence of recurrent stroke (Figure 2d and Table 2). In age- and sex-adjusted and fully adjusted analyses, there was no statistically significant difference in the risk of recurrence between lacunar/SVD versus other ischaemic stroke subtypes over the entire follow-up period (fully adjusted HR: 0.84, 95% CI 0.61 to 1.15), or when restricting the time period to 0-1 year and to one-year onwards (Table 3).

There were 79 MI events ([52-27](#) and [27-52](#) among those with lacunar/SVD and other ischaemic stroke, respectively), with the cumulative incidence of MI similar in both groups at 1, 5 and 10 years (Figure 2c and Table 2). In age- and sex-adjusted analyses there was no statistically significant difference in risk of MI between lacunar/SVD versus other ischaemic stroke (HR 1.0, 95% CI 0.62 to 1.65; Table 3). Similar results were obtained when adjusting for additional confounders and when examining the 0-1 year and 1-year onwards time-periods (Table 3).

We observed similar associations for recurrent stroke and MI risk when we accounted for the competing risk of death. When stratifying by inpatient/outpatient status results were similar among inpatients as in our primary analysis, but there were no differences in death or recurrent stroke among lacunar/SVD versus other ischaemic stroke patients assessed as outpatients (Supplementary Tables 2 and 3).

In secondary analyses using the mechanistic (TOAST-based) classification, 224 ischaemic strokes were classified as SVD, 82 as LVD and 141 as CE. A large proportion of ischaemic strokes (53.7%) had no determined mechanistic subtype due to having either more than one potential aetiology or undetermined aetiology, and so were excluded (Supplementary Table 4). We obtained similar results to the primary analyses when comparing cumulative incidence of mortality, recurrent stroke and MI at one, five and 10 years among SVD versus non-SVD ischaemic subtypes, although differences were generally more marked between SVD and CE than SVD and LVD stroke. Results of survival analyses were broadly similar to those from primary analyses for each outcome (Supplementary Tables 5 and 6).

DISCUSSION

During 14 years of follow-up, our study found that, in the long-term, all-cause mortality was only slightly lower in patients with lacunar/SVD stroke compared to other ischaemic stroke subtypes. There was no clear difference in the long-term risk of recurrent stroke or MI, although relatively wide estimates did not preclude lower risks in people with lacunar/SVD strokes.

Our findings on long-term mortality generally align with a number of previous studies with five or more years of follow-up, which found similar or only slightly lower mortality rates between lacunar/SVD versus other ischaemic stroke comparison groups.^{8, 10, 12, 16-23} In contrast to this, one study reported a marked increased mortality risk in people with lacunar/SVD stroke, as compared to other ischaemic stroke,¹¹ but this may be due to the inclusion of a selected population with very high rates of prior cardiac comorbidities. We found no significant difference in the very long-term risk of recurrent stroke, although relatively wide CIs did not exclude the possibility of a slightly lower risk in the lacunar/SVD group. This is largely in keeping with other studies^{9, 10, 12, 16, 20, 22, 24}, including contemporaneous studies^{12, 16, 22, 24}, which similarly found no difference in long-term risk of recurrent stroke risk among people with lacunar/SVD versus other ischaemic stroke. Findings on MI risk across the small number of existing studies that have reported on this are inconsistent. Among just four studies reporting on a total of 270 MI or acute coronary events, two found no difference^{10, 25}, and two found a lower risk of MI in those with lacunar/SVD stroke.^{12, 24} This may have been due to: small numbers of MI events in some studies^{10, 25}; differences in the composition of the non-lacunar/SVD comparison group; and inclusion of all acute coronary events in some studies.

Our study has various strengths. We included a prospectively recruited cohort of stroke patients which comprised both inpatients and outpatients, resulting in a study population which, in this particular setting, is more representative of the general stroke population than studies based on hospital admitted strokes only. Patients were carefully phenotyped in terms of ischaemic stroke subtype classification using the OCSF classification,² which has high inter-rater reliability, is predictive of clinical outcomes and is widely used in clinical trials and epidemiological studies.^{26, 27} Recurrent strokes occurring within the first year of stroke are particularly well captured, given our multiple hot pursuit methods and use of advanced brain imaging where possible. The capacity for health record linkage in Scotland facilitated long-term follow-up, resulting in one of the largest long-term

follow-up studies of ischaemic stroke subtypes, including for the occurrence of MI which has previously rarely been reported.

Our study does have limitations. Although widely used in clinical trials and epidemiological studies, the OCSF classification does have the potential for misclassification of stroke ischaemic stroke subtypes. Assignment of OCSF based on clinical symptoms alone results in approximately 20 percent of lacunar strokes being misclassified as cortical stroke and vice versa.^{28, 29} However, we sought to mitigate this potential for misclassification by using a clinical and imaging-based approach, thus reducing this misclassification. Unfortunately our study was not resourced to perform MRI on all index strokes and so some residual misclassification of ischaemic stroke subtypes is likely.³⁰⁻³² The alternative mechanistic classification method available at the time of patient recruitment was the TOAST classification¹⁴, which was limited by concerns around the definition of lacunar stroke and the large proportion of patients with multiple or no determined causes.^{33, 34} Whilst new aetiological ischaemic stroke classifications have been developed since, these remain hampered by important limitations, including reliability, validity and ease of application in a clinical setting.³⁵ Our study will not have captured recurrent strokes assessed in outpatients beyond the first year of follow-up. Since people with lacunar/SVD strokes may be more likely to have a lacunar/SVD recurrence^{7, 33} and lacunar/SVD strokes are more likely than other stroke subtypes to be assessed in an outpatient setting, we may have underestimated the longer term risk of recurrent stroke, particularly in lacunar/SVD stroke patients. Using routinely collected data may also introduce the possibility of diagnostic or recording errors.³⁶ Unfortunately we were unable to adjust for stroke severity. However, it is interesting that analysis by inpatient/outpatient assessment status (used as a proxy for severity) found similar findings for inpatients but not outpatients. [The requirement for consent meant that not all eligible patients were included. However, as shown previously³⁷, we recruited 88% of eligible patients and found no difference in age, sex and stroke subtype distribution between participants and non-participants. We did find that participants were more likely to be admitted to a stroke unit and were more affluent.](#) Finally, some loss to follow-up may have occurred through migration out of Scotland, but this will be minimal given the age of our cohort and migration occurring mainly among younger people.³⁸

[The results of our study](#)~~Our findings~~ emphasise the need for clinicians, patients and carers to recognise the non-benign nature of lacunar/SVD stroke, despite symptoms being milder than other types of ischaemic stroke and the importance of adhering to secondary prevention medication. [These findings complement the evidence from](#)

randomised controlled trials ~~which demonstrates that on~~ the relative effect of statins and blood pressure lowering and antiplatelet medications over the long-term does not ~~show differences in relative effects~~differ between ischaemic stroke subtypes.³⁹ ~~Our findings from observational data complement this evidence,~~ Our findings that lacunar ischaemic patients have a similar prognosis for relevant outcomes as other ischaemic stroke patients, and therefore as much to gain through long term preventive efforts, helps to emphasise the importance of such preventive efforts in all ischaemic stroke patients, as per clinical guidelines. ~~highlighting the need for appropriate optimal secondary prevention following stroke to be carefully managed irrespective of ischaemic stroke subtype.~~ Under ideal circumstances, secondary stroke prevention treatment is thought to reduce risk of recurrent stroke by about 80%.⁴⁰ However, secondary prevention has been shown to be sub-optimal, through failure to successfully translate evidence-based recommendations into clinical practice, particularly in low income countries.⁴⁰ Non-adherence to prescribed secondary prevention medication increases with time from stroke and is associated with low perceived benefit of medication and younger age.^{40, 41}

Further research, including pooling of relevant studies to improve study power and harmonise key definitions, is needed to conclusively establish whether MI risk differs between lacunar/SVD versus other ischaemic stroke subtypes. We should also identify reasons for sub-optimal implementation of clinical guidelines on secondary prevention and determine whether adherence differs between those with lacunar versus other stroke subtypes.

Conclusion

In the long-term, patients with lacunar/SVD stroke may have only a slightly lower risk of death compared to patients with other ischaemic strokes. There is no conclusive evidence that recurrent stroke and MI risks differ between these groups. Patients and physicians should be as vigilant in optimising short and long-term secondary prevention of vascular events among patients following lacunar/SVD stroke as for other types of ischaemic stroke.

Figure legends

Figure 1 Flow diagram of patients included from the Edinburgh Stroke Study and assigned an anatomical and/or mechanistic ischaemic stroke subtype classification

CE = cardioembolic; LVD = large vessel disease; OSCP = Oxfordshire Community Stroke Project; POCS = posterior circulation stroke; SVD = small vessel disease; TOAST = Trial of Org 10172 in Acute Stroke Treatment

Figure 2 Kaplan-Meier survival graphs showing cumulative incidence of (A) all-cause mortality, (B) recurrent stroke and (C) myocardial infarction, among people with lacunar (dotted line) and other (non-lacunar) ischaemic stroke (solid line)

REFERENCES

1. Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet Glob Health* 2013; 1: e259-281. DOI: 10.1016/S2214-109X(13)70089-5.
2. Ornello R, Degan D, Tiseo C, et al. Distribution and Temporal Trends From 1993 to 2015 of Ischemic Stroke Subtypes: A Systematic Review and Meta-Analysis. *Stroke* 2018; 49: 814-819. DOI: 10.1161/STROKEAHA.117.020031.
3. Behrouz R, Malek AR and Torbey MT. Small vessel cerebrovascular disease: the past, present, and future. *Stroke Res Treat* 2012; 2012: 839151. DOI: 10.1155/2012/839151.
4. Norrving B. Long-term prognosis after lacunar infarction. *Lancet Neurol* 2003; 2: 238-245. DOI: 10.1016/s1474-4422(03)00352-1.
5. Makin SDJ, Turpin S, Dennis MS, et al. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes. *JNNP* 2013; 84: 893-900. DOI: 10.1136/jnnp-2012-303645.
6. Jackson C and Sudlow C. Comparing risks of death and recurrent vascular events between lacunar and non-lacunar infarction. *Brain* 2005; 128: 2507-2517. DOI: 10.1093/brain/awh636.
7. Jackson CA, Hutchison A, Dennis MS, et al. Differences between ischemic stroke subtypes in vascular outcomes support a distinct lacunar ischemic stroke arteriopathy: a prospective, hospital-based study. *Stroke* 2009; 40: 3679-3684. DOI: 10.1161/STROKEAHA.109.558221.
8. Eriksson SE and Olsson JE. Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study. *Cerebrovasc Dis* 2001; 12: 171-180. DOI: 10.1159/000047700.
9. Jones SB, Sen S, Lakshminarayan K, et al. Poststroke outcomes vary by pathogenic stroke subtype in the Atherosclerosis Risk in Communities Study. *Stroke* 2013; 44: 2307-2310. DOI: 10.1161/STROKEAHA.113.000830.
10. Lv Y, Fang X, Asmaro K, et al. Five-year prognosis after mild to moderate ischemic stroke by stroke subtype: a multi-clinic registry study. *PloS One* 2013; 8: e75019. DOI: 10.1371/journal.pone.0075019.
11. Melkas S, Putaala J, Oksala NKJ, et al. Small-vessel disease relates to poor poststroke survival in a 12-year follow-up. *Neurology* 2011; 76: 734-739. DOI: 10.1212/WNL.0b013e31820db666.
12. Ntaios G, Papavasileiou V, Makaritsis K, et al. Association of ischaemic stroke subtype with long-term cardiovascular events. *Eur J Neurol* 2014; 21: 1108-1114. DOI: 10.1111/ene.12438.
13. Aho K, Harmsen P, Hatano S, et al. Cerebrovascular disease in the community: results of a WHO collaborative study. *Bull World Health Organ* 1980; 58: 113-130.
14. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 1993; 24: 35-41. DOI: 10.1161/01.str.24.1.35.
15. Woodfield R, Grant I, Group UBSO, et al. Accuracy of Electronic Health Record Data for Identifying Stroke Cases in Large-Scale Epidemiological Studies: A Systematic Review from the UK Biobank Stroke Outcomes Group. *PloS One* 2015; 10: e0140533. DOI: 10.1371/journal.pone.0140533.
16. Cabral NL, Nagel V, Conforto AB, et al. High five-year mortality rates of ischemic stroke subtypes: A prospective cohort study in Brazil. *International journal of stroke : official journal of the International Stroke Society* 2019; 14: 491-499. 2018/10/10. DOI: 10.1177/1747493018806197.
17. de Jong G, van Raak L, Kessels F, et al. Stroke subtype and mortality. a follow-up study in 998 patients with a first cerebral infarct. *J Clin Epidemiol* 2003; 56: 262-268. DOI: 10.1016/s0895-4356(02)00572-3.
18. Kaplan RC, Tirschwell DL, Longstreth WT, et al. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. *Neurology* 2005; 65: 835-842. DOI: 10.1212/01.wnl.0000176058.09848.bb.
19. Sacco S, Marini C, Totaro R, et al. A population-based study of the incidence and prognosis of lacunar stroke. *Neurology* 2006; 66: 1335-1338. DOI: 10.1212/01.wnl.0000210457.89798.0e.
20. Sacco SE, Whisnant JP, Broderick JP, et al. Epidemiological characteristics of lacunar infarcts in a population. *Stroke* 1991; 22: 1236-1241. DOI: 10.1161/01.str.22.10.1236.
21. Saber H, Thrift AG, Kapral MK, et al. Incidence, recurrence, and long-term survival of ischemic stroke subtypes: A population-based study in the Middle East. *International journal of stroke : official journal of the International Stroke Society* 2017; 12: 835-843. 2017/01/04. DOI: 10.1177/1747493016684843.
22. Bjerkreim AT, Khanevski AN, Thomassen L, et al. Five-year readmission and mortality differ by ischemic stroke subtype. *Journal of the neurological sciences* 2019; 403: 31-37. 2019/06/12. DOI: 10.1016/j.jns.2019.06.007.
23. Fang X-H, Wang W-H, Zhang X-Q, et al. Incidence and survival of symptomatic lacunar infarction in a Beijing population: a 6-year prospective study. *Eur J Neurol* 2012; 19: 1114-1120. DOI: 10.1111/j.1468-1331.2012.03709.x.

24. Li L, Yiin GS, Geraghty OC, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. *Lancet Neurol* 2015; 14: 903-913. DOI: 10.1016/S1474-4422(15)00132-5.
25. Rincon F, Dhamoon M, Moon Y, et al. Stroke location and association with fatal cardiac outcomes: Northern Manhattan Study (NOMAS). *Stroke* 2008; 39: 2425-2431. DOI: 10.1161/STROKEAHA.107.506055.
26. Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. *Lancet* 1991; 337: 1521-1526. DOI: 10.1016/0140-6736(91)93206-o.
27. Pittock SJ, Meldrum D, Hardiman O, et al. The Oxfordshire Community Stroke Project classification: correlation with imaging, associated complications, and prediction of outcome in acute ischemic stroke. *J Stroke Cerebrovasc Dis* 2003; 12: 1-7. DOI: 10.1053/jscd.2003.7.
28. Giacomozzi S, Caso V, Agnelli G, et al. Lacunar stroke syndromes as predictors of lacunar and non-lacunar infarcts on neuroimaging: a hospital-based study. *Internal and emergency medicine* 2020; 15: 429-436. 2019/09/20. DOI: 10.1007/s11739-019-02193-2.
29. Potter G, Doubal F, Jackson C, et al. Associations of Clinical Stroke Misclassification ('Clinical-Imaging Dissociation') in Acute Ischemic Stroke. *Cerebrovasc Dis* 2010; 29: 395-402. DOI: 10.1159/000286342.
30. Al-Buhairi AR, Phillips SJ, Llewellyn G, et al. Prediction of infarct topography using the Oxfordshire Community Stroke Project classification of stroke subtypes. *J Stroke Cerebrovasc Dis* 1998; 7: 339-343. DOI: 10.1016/s1052-3057(98)80052-9.
31. E. MG, M. WJ, S. DM, et al. Relationship Between Pattern of Intracranial Artery Abnormalities on Transcranial Doppler and Oxfordshire Community Stroke Project Clinical Classification of Ischemic Stroke. *Stroke* 2000; 31: 714-719. DOI: 10.1161/01.STR.31.3.714.
32. Wardlaw JM, Dennis MS, Lindley RJ, et al. The validity of a simple clinical classification of acute ischaemic stroke. *J Neurol* 1996; 243: 274-279. DOI: 10.1007/BF00868526.
33. Jackson C and Sudlow C. Are Lacunar Strokes Really Different?: A Systematic Review of Differences in Risk Factor Profiles Between Lacunar and Nonlacunar Infarcts. *Stroke* 2005; 36: 891-901. DOI: 10.1161/01.STR.0000157949.34986.30.
34. Landau WM and Nassief A. Editorial comment--time to burn the TOAST. *Stroke* 2005; 36: 902-904. 2005/04/01.
35. Radu RA, Terecoasă EO, Băjenaru OA, et al. Etiologic classification of ischemic stroke: Where do we stand? *Clinical Neurology and Neurosurgery* 2017; 159: 93-106. DOI: 10.1016/j.clineuro.2017.05.019.
36. Turner M, Barber M, Dodds H, et al. Agreement between routine electronic hospital discharge and Scottish Stroke Care Audit (SSCA) data in identifying stroke in the Scottish population. *BMC Health Serv Res* 2015; 15: 583. DOI: 10.1186/s12913-015-1244-y.
37. Jackson C, Crossland L, Dennis M, et al. Assessing the impact of the requirement for explicit consent in a hospital-based stroke study. *QJM: monthly journal of the Association of Physicians* 2008; 101: 281-289. 2008/02/19. DOI: 10.1093/qjmed/hcm152.
38. Research SGS. *Demographic Change in Scotland*. 2010. Edinburgh.
39. Esenwa C and Gutierrez J. Secondary stroke prevention: challenges and solutions. *Vasc Health Risk Manag* 2015; 11: 437-450. DOI: 10.2147/VHRM.S63791.
40. Hankey GJ. Secondary stroke prevention. *Lancet Neurol* 2014; 13: 178-194. DOI: 10.1016/S1474-4422(13)70255-2.
41. Al AlShaikh S, Quinn T, Dunn W, et al. Predictive factors of non-adherence to secondary preventative medication after stroke or transient ischaemic attack: A systematic review and meta-analyses. *Eur Stroke J* 2016; 1: 65-75. DOI: 10.1177/2396987316647187.

Table 1. Baseline characteristics of patients with lacunar/SVD and other ischaemic stroke subtypes

Characteristic	Lacunar/SVD stroke (N=283) n (%)	Other ischaemic stroke subtypes (N=529) n (%)	P-value*
Age at stroke (mean years $\pm$ SD)	68.7 (11.9)	72.5 (11.7)	0.46
Male	170 (60.1)	252 (47.6)	0.001
Prior TIA	49 (17.3)	96 (18.2)	0.76
Hypertension [†]	134 (47.3)	277 (52.4)	0.13
Diabetes mellitus [‡]	36 (12.7)	55 (10.4)	0.32
Prior IHD [§]	57 (20.1)	144 (27.2)	0.03
Cardiac failure [¶]	10 (3.5)	35 (6.6)	0.07
Atrial fibrillation ^{**}	27 (9.6)	107 (20.2)	<0.001
Ipsilateral carotid stenosis ^{††}	15 (5.3)	95 (18.0)	<0.001
Smoking	108 (38.4)	153 (29.3)	0.008
Alcohol units/week, median (IQR)	4 (0-15)	1 (0-10)	0.2
Independent in ADL before stroke	276 (97.5)	499 (94.5)	0.05
CT performed	221 (78.1)	443 (83.7)	0.04
MRI performed	73 (25.8)	116 (21.9)	0.21

*P-value for
statistical test of

difference between SVD/lacunar versus other ischaemic stroke

[†]Treated hypertension in medical history

[‡]Diagnosis of or using medication for diabetes mellitus

[§]MI, angina or coronary revascularization in medical history

[¶]Clinical signs of heart failure or taking at least two drugs for its treatment

^{**}History of paroxysmal or persistent atrial fibrillation

^{††} $\geq 70\%$ internal carotid artery stenosis (missing in 11 patients with Lacunar/SVD stroke and 43 patients with other ischaemic stroke subtypes)

ADL = activities of daily living; CT = computed tomography; IHD = ischaemic heart disease; IQR = interquartile range; MRI = magnetic resonance imaging; OCSP = Oxfordshire Community Stroke Project Subtype Classification; TIA = transient ischaemic attack

Table 2. Cumulative incidence of mortality, recurrent stroke and myocardial infarction at 1, 5 and 10 years, in patients with lacunar/SVD and other (non-lacunar/non-SVD) ischaemic stroke subtypes

	Lacunar/SVD (N=283)		Other ischaemic stroke subtypes (N=529)	
Outcome	Number of events	Cumulative incidence (95% CI)	Number of events	Cumulative incidence (95% CI)
Mortality				
1 year	16	5.7 (3.5-9.1)	83	15.7 (12.9-19.1)
5 years	63	22.3 (17.9-27.6)	205	38.8 (34.8-43.1)
10 years	128	45.2 (39.7-51.2)	309	58.4 (54.3-62.6)
Recurrent stroke				
1 year	21	7.6 (5.0-11.4)	49	9.9 (12.9-7.6)
5 years	43	16.3 (12.4-21.4)	91	20.1 (16.7-24.2)
10 years	55	22.3 (17.5-28.1)	118	29.2 (24.9-34.2)
Myocardial infarction				
1 year	6	2.2 (1.0-4.8)	16	3.3 (2.0-5.3)
5 years	13	5.0 (2.9-8.5)	40	9.3 (6.9-12.5)
10 years	25	11.1 (7.6-16.1)	47	11.9 (8.9-15.6)

CI = confidence interval; SVD = small vessel disease

Table 3. Hazard ratios from Cox proportional hazard regression analyses for all-cause mortality, recurrent stroke and myocardial infarction, comparing lacunar/SVD versus other (non-lacunar/non-SVD) ischaemic stroke subtypes, by follow-up time period

	Entire follow-up period*	0-1 year	1 year onwards
Outcome	HR (95% CI)	HR (95% CI)	HR (95% CI)
Mortality	(n=508)	(n=95)	(n=413)
Age-and sex-adjusted	0.75 (0.62-0.91) [†]	0.43 (0.25-0.74) [†]	0.83 (0.67-1.01) [†]
Fully adjusted [§]	0.79 (0.65-0.95) [¶]	0.49 (0.28-0.84) ^{**}	0.86 (0.70-1.05) ^{**}
Recurrent stroke	(n=180)	(n=69)	(n=111)
Age- and sex-adjusted	0.80 (0.59-1.10) ^{††}	0.79 (0.47-1.33) ^{††}	0.81 (0.55-1.20) ^{††}
Fully adjusted [§]	0.84 (0.61-1.15) ^{††}	0.82 (0.48-1.40) ^{††}	0.84 (0.57-1.25) ^{††}
Myocardial infarction	(n=79)	(n=22)	(n=57)
Age- and sex-adjusted	0.82 (0.51-1.31) ^{††}	0.74 (0.29-1.92) ^{††}	0.91 (0.53-1.56) ^{††}
Fully adjusted ^{††}	0.83 (0.52-1.34) ^{††}	NC	0.93 (0.54-1.60) ^{††}

*800 people with complete information on all covariates included in analyses for the entire time period

[†]P-value 0.002

[‡]p-value 0.06

[§]In addition to age and sex, also adjusted for history of ischaemic heart disease, atrial fibrillation, history of cardiac failure and smoking status (all of which were associated with type of stroke and had none or almost no missing values); inclusion of independence in activities of daily living (ADL) did not contribute to the fit of the model and so was not included in the final fully adjusted model

[¶]P-value 0.02

^{**}p-value 0.01

^{††}p-value >0.05

^{††}Adjusted for age, sex, history of ischaemic heart disease, atrial fibrillation and smoking (not adjusted for history of cardiac failure due to smaller number of outcome events)

CI = confidence interval; HR = hazard ratio; n = number of deaths, recurrent strokes or myocardial infarction events occurring during each time period; NC = not calculated (too few myocardial infarctions within the first year to adjust for additional covariates); SVD = small vessel disease

Long-term mortality and recurrent vascular events in lacunar versus non-lacunar ischemic stroke: a cohort study

Portegijs S (MSc)^{1,2*}, Ong AY (MBChB)^{3*}, Halbesma N (PhD)¹, Hutchinson A (MSc)^{1,4}, Sudlow CLM (DPhil)^{1,4} Jackson CA (PhD)^{1†}

Supplementary material

Supplementary Table 1 Description of the OCSF-based anatomical classification and the TOAST-based mechanistic classification methods

<u>Category</u>	<u>Description</u>
<u>OCSP-based anatomical classification</u>	
<u>SVD/lacunar infarction (LACI)</u>	<p>i. <u>Clinical presentation with any of:</u></p> <ul style="list-style-type: none"> - <u>Pure motor stroke</u> - <u>Pure sensory stroke</u> - <u>Sensorimotor stroke</u> <p><u>(with the above deficit involving at least two contiguous areas out of three of the whole of the face, arm and leg)</u></p> <ul style="list-style-type: none"> - <u>Ataxic hemiparesis</u> <p><u>AND</u></p> <p><u>Either no visible relevant infarct or a visible relevant subcortical infarct (located in the thalamus, basal ganglia, internal or external capsule or centrum semiovale) measuring $\leq 20\text{mm}$ on brain imaging)</u></p> <p>ii. <u>A cortical syndrome with a relevant subcortical infarct that accounted for their symptoms</u></p>
<u>Non-lacunar (partial anterior circulation infarction [PACI] or total anterior circulation infarction [TACI])</u>	<ul style="list-style-type: none"> ▪ <u>Presentation with a cortical-involving anterior circulation syndrome with or without an accompanying visible relevant cortical or striatocapsular infarct on brain imaging</u> <p><u>OR</u></p> <ul style="list-style-type: none"> ▪ <u>Presentation with a clinical lacunar or posterior circulation syndrome but with a cortical-involving or striatocapsular infarct in the anterior circulation territory that was clearly relevant to the presenting stroke</u>
<u>Posterior circulation infarction (POCI)</u>	<ul style="list-style-type: none"> ▪ <u>Presentation with a posterior circulation syndrome with or without an accompanying relevant infarct on brain imaging, or with an anterior or cortical syndrome but a visible relevant infarct in the posterior circulation</u>
<u>Modified TOAST-based mechanistic classification</u>	
<u>Small vessel disease</u>	<ul style="list-style-type: none"> ▪ <u>Clinical findings of one of the lacunar syndromes should be present. Brain imaging should be normal or show a relevant brain stem or subcortical hemispheric lesion of diameter $<1.5\text{cm}$</u> ▪ <u>A history of diabetes mellitus or hypertension supports the diagnosis</u> ▪ <u>Potential cardiac sources of embolism, such as AF, should be absent, and the large extracranial arteries should not demonstrate $\geq 70\%$ stenosis*</u>
<u>Large vessel disease</u>	<ul style="list-style-type: none"> ▪ <u>Clinical findings include cortical, cerebellar, or brain stem dysfunction and on brain imaging cortical, cerebellar, brain stem or subcortical lesions $>1.5\text{cm}$ are considered to be of potential large artery atherosclerotic origin</u> ▪ <u>Diagnosis requires supportive evidence by duplex imaging or arteriography of $\geq 70\%$* stenosis of an appropriate intracranial or extracranial artery</u>

<u>Cardioembolism</u>	<ul style="list-style-type: none"> ▪ <u>Potential sources of cardiogenic embolism, such as AF should be excluded, and history of TIAs in the same vascular territory supports the clinical diagnosis</u> ▪ <u>Clinical and brain imaging findings are similar to those described for large artery atherosclerosis</u> ▪ <u>At least 1 cardiac source of embolism, such as AF, must be identified. Previous TIAs in >1 vascular territory supports the diagnosis</u> ▪ <u>Potential large artery atherosclerotic sources of thrombosis or embolism should be absent</u>
<u>'Other' aetiology</u>	
<u>I. Multiple aetiologies</u>	<u>Includes patients with ≥2 potential causes of stroke (e.g. AF and >70% stenosis of extracranial arteries)</u>
<u>II. Undetermined aetiology with complete investigation</u>	<u>Includes patients with no identifiable cause of stroke following complete investigation</u>
<u>III. Undetermined aetiology with incomplete investigation</u>	<u>Includes patients with no identifiable cause of stroke following incomplete investigation</u>

*Using the European Carotid Surgery scale for measuring stenosis, which is equivalent to 50% on the North American Symptomatic Carotid Endarterectomy Trial scale

AF = atrial fibrillation; OCSP = Oxfordshire Community Stroke Project; TIA = transient ischaemic attack; TOAST = Trial of Org 10172 in Acute Stroke Treatment

Supplementary Table 2 Subdistribution hazard ratios from Cox proportional hazard regression analyses, accounting for competing risk of death, for recurrent stroke and MI, comparing lacunar/SVD vs other ischaemic stroke subtypes (as defined by OCSF-based anatomical classification), by time period

Outcome	Time period		
	Entire follow-up	0-1 year	1 year onwards
Recurrent stroke			
Age- and sex-adjusted	0.92 (0.67 to 1.26)	0.87 (0.52 to 1.5)	0.88 (0.59 to 1.3)
Fully adjusted*	0.93 (0.67 to 1.26)	0.84 (0.50 to 1.4)	0.9 (0.60 to 1.3)
Myocardial infarction			
Age- and sex-adjusted	0.99 (0.61 to 1.61)	0.74 (0.27 to 2.01)	1.00 (0.58 to 1.74)
Fully adjusted*	0.95 (0.58 to 1.56)	NC	0.95 (0.54 to 1.66) [†]

*Adjusted for age, sex, prior ischaemic heart disease, atrial fibrillation, prior cardiac failure and smoking

[†]Due to smaller number of events, adjusted for age, sex, prior ischaemic heart disease, atrial fibrillation and smoking (and not prior cardiac failure)

NC = not calculated (too few events to adjust for covariates other than age and sex)

Supplementary Table 3 Hazard ratios from Cox proportional hazard regression analyses for OCSP-based anatomical classification for all-cause mortality and recurrent stroke, split by different time periods and stratified by inpatient and outpatient status, comparing lacunar/SVD vs other ischaemic stroke subtypes

Outcome	Inpatients (N = 363)			Outpatients (N = 449)		
	Entire follow-up	Year	1-year onward	Entire follow-up	year	1 year onwards
Mortality	(n= 266)	(n = 83)	(n = 183)	(n = 253)	(n = 17)	(n = 256)
Age-and sex-adjusted	0.60 (0.45-0.80)	0.40 (0.22-0.74)	0.69 (0.50-0.95)	0.93 (0.72-1.20)	0.94 (0.73-1.21)	0.94 (0.72-1.23)
Fully adjusted*	0.67 (0.50-0.90)	0.44 (0.23-0.85)	0.75 (0.54-1.04)	0.92 (0.71-1.20)	NC	0.93 (0.72-1.22)
Recurrent stroke	(n = 86)	(n = 36)	(n = 50)	(n = 95)	(n = 32)	(n = 63)
Age-and sex-adjusted	0.74 (0.47-1.17)	0.85 (0.42-1.73)	0.67 (0.37-1.22)	0.76 (0.49-1.18)	0.68 (0.32-1.45)	0.84 (0.49-1.45)
Fully adjusted*	0.78 (0.48-1.26)	NC	0.65 (0.35-1.22)	0.76 (0.48-1.19)	NC	0.78 (0.44-1.36)

*Adjusted for age, sex, smoking, history of ischaemic heart disease, history of heart failure and atrial fibrillation

NC = not calculated (given too few outcomes)

Supplementary Table 4 Baseline characteristics of participants, by ischaemic subtype category defined according to mechanistic TOAST-based classification

<u>Characteristic</u>	<u>SVD</u> <u>(N=224)</u> <u>n (%)</u>	<u>Non-SVD*</u> <u>(N=223)</u> <u>n (%)</u>	<u>LVD</u> <u>(N=82)</u> <u>n (%)</u>	<u>CE</u> <u>(N=141)</u> <u>n (%)</u>	<u>Other†</u> <u>(N=520)</u> <u>n (%)</u>
<u>Age at stroke (mean ± SD)</u>	<u>67.8 (12.0)</u>	<u>74.2 (10.7)</u>	<u>70.6 (10.3)</u>	<u>76.3(10.4)</u>	<u>71.2</u> <u>(11.7)</u>
<u>Male</u>	<u>135 (60.3)</u>	<u>113 (50.7)</u>	<u>45 (54.9)</u>	<u>68 (48.2)</u>	<u>250</u> <u>(48.1)</u>
<u>Prior TIA</u>	<u>37 (16.5)</u>	<u>37 (16.7)</u>	<u>17 (20.7)</u>	<u>20 (14.3)</u>	<u>91 (17.5)</u>
<u>Hypertension‡</u>	<u>107 (47.8)</u>	<u>121 (54.5)</u>	<u>46 (56.1)</u>	<u>75 (53.6)</u>	<u>256</u> <u>(49.2)</u>
<u>Diabetes mellitus§</u>	<u>29 (12.9)</u>	<u>28 (12.6)</u>	<u>12 (14.6)</u>	<u>16 (11.3)</u>	<u>54 (10.4)</u>
<u>Prior IHD¶</u>	<u>41 (18.3)</u>	<u>69 (30.9)</u>	<u>16 (19.5)</u>	<u>53 (37.6)</u>	<u>125</u> <u>(24.0)</u>
<u>Cardiac failure**</u>	<u>5 (2.2)</u>	<u>23 (10.4)</u>	<u>3 (3.7)</u>	<u>20 (14.3)</u>	<u>26 (5.0)</u>
<u>Atrial fibrillation††</u>	<u>0 (0)</u>	<u>91 (40.8)</u>	<u>0 (0)</u>	<u>91 (64.5)</u>	<u>64 (12.3)</u>
<u>Ipsilateral carotid Stenosis‡‡</u>	<u>-</u>	<u>82 (36.8)</u>	<u>82 (100)</u>	<u>-</u>	<u>30 (5.8)</u>
<u>Smoking</u>	<u>90 (40.4)</u>	<u>62 (28.2)</u>	<u>36 (45.0)</u>	<u>26 (18.6)</u>	<u>146</u> <u>(28.5)</u>
<u>Alcohol units/week, median (IQR)</u>	<u>4 (0-15)</u>	<u>1 (0-8)</u>	<u>2 (0-10)</u>	<u>1 (0-8)</u>	<u>1 (0-10)</u>
<u>Independent in ADL before Stroke</u>	<u>220 (98.2)</u>	<u>213 (95.5)</u>	<u>78 (95.1)</u>	<u>135 (95.7)</u>	<u>491</u> <u>(94.6)</u>
<u>CT</u>	<u>175 (78.1)</u>	<u>187 (83.9)</u>	<u>73 (89.0)</u>	<u>114 (80.9)</u>	<u>421</u> <u>(81.0)</u>
<u>MRI</u>	<u>56 (25.0)</u>	<u>48 (21.6)</u>	<u>13 (16.0)</u>	<u>35 (24.8)</u>	<u>136</u> <u>(26.2)</u>

*Non-SVD = LVD plus CE strokes

†'Other' includes strokes: with multiple aetiologies; undetermined aetiology despite complete investigation and undetermined aetiology with incomplete investigation

‡Treated hypertension in medical history

§Diagnosis of or using medication for diabetes mellitus

¶MI, angina or coronary revascularization in medical history

**Clinical signs of heart failure or taking at least two drugs for its treatment

††History of or post stroke electrocardiogram evidence of paroxysmal or persistent atrial fibrillation

‡‡≥70% internal carotid artery stenosis, based on the European Carotid Surgery scale for measuring stenosis, which is equivalent to 50% on the North American Symptomatic Carotid Endarterectomy Trial scale (there are no values in the SVD or CE columns since ipsilateral carotid stenosis is incorporated into the definition of these subtypes)

ADL = activities of daily living; CE = cardioembolic; CT = computed tomography; IHD = ischaemic heart disease; IQR: = interquartile range; LVD = large vessel disease; MRI = magnetic resonance imaging; SVD = small vessel disease; TIA = transient ischaemic attack

Supplementary Table 5 Cumulative incidence of mortality, recurrent stroke and myocardial infarction by ischaemic stroke subtype, defined according to mechanistic TOAST-based classification

<u>Outcome</u>	<u>Small vessel disease (N = 224)</u>		<u>Large vessel disease (N = 82)</u>		<u>Cardioembolic (N =141)</u>	
	<u>Number of events</u>	<u>Cumulative incidence (95% CI)</u>	<u>Number of events</u>	<u>Cumulative incidence (95% CI)</u>	<u>Number of events</u>	<u>Cumulative incidence (95% CI)</u>
<u>Mortality</u>						
<u>1 year</u>	<u>8</u>	<u>3.6 (1.8 to 7.0)</u>	<u>10</u>	<u>12.2 (6.8 to 21.5)</u>	<u>29</u>	<u>20.6 (14.8 to 28.2)</u>
<u>5 years</u>	<u>47</u>	<u>21.0 (16.2 to 26.9)</u>	<u>33</u>	<u>40.2 (30.6 to 51.7)</u>	<u>73</u>	<u>51.8 (43.8 to 60.2)</u>
<u>10 years</u>	<u>94</u>	<u>42.0 (35.8 to 48.7)</u>	<u>53</u>	<u>64.6 (54.4 to 74.8)</u>	<u>101</u>	<u>71.6 (64.1 to 78.8)</u>
<u>Recurrent stroke</u>						
<u>1 year</u>	<u>15</u>	<u>6.8 (4.2 to 11.0)</u>	<u>16</u>	<u>11.5 (6.2 to 21.0)</u>	<u>16</u>	<u>12.3 (7.7 to 19.3)</u>
<u>5 years</u>	<u>34</u>	<u>16.1 (11.8 to 21.8)</u>	<u>17</u>	<u>22.7 (14.4 to 34.6)</u>	<u>31</u>	<u>27.7 (20.1 to 37.2)</u>
<u>10 years</u>	<u>43</u>	<u>21.5 (16.4 to 28.0)</u>	<u>18</u>	<u>25.0 (16.1 to 37.6)</u>	<u>38</u>	<u>38.4 (29.0 to 49.6)</u>
<u>Myocardial infarction</u>						
<u>1 year</u>	<u>2</u>	<u>0.9 (0.2 to 3.6)</u>	<u>1</u>	<u>1.3 (0.2 to 8.9)</u>	<u>6</u>	<u>4.7 (2.1 to 10.2)</u>
<u>5 years</u>	<u>9</u>	<u>4.4 (2.3 to 8.4)</u>	<u>5</u>	<u>7.8 (3.3 to 17.8)</u>	<u>10</u>	<u>9.2 (5.0 to 16.7)</u>
<u>10 years</u>	<u>18</u>	<u>10.2 (6.5 to 15.7)</u>	<u>7</u>	<u>12.1 (5.9 to 24.1)</u>	<u>12</u>	<u>12.5 (7.1 to 21.5)</u>

CI = confidence interval; TOAST = Trial of Org 10172 in Acute Stroke Treatment

Supplementary Table 6 Hazard ratios for risk of all-cause mortality, recurrent stroke and myocardial infarction, comparing stroke attributed to SVD versus non-SVD (i.e. LVD or CE), by time period

<u>Outcome</u>	<u>HR (95% CI)</u>		
	<u>Entire follow-up*</u>	<u>0-1 year</u>	<u>1 year onwards</u>
<u>Mortality</u>			
<u>Age- and sex-adjusted</u>	<u>0.60 (0.47 to 0.76)[†]</u>	<u>0.25 (0.11 to 0.53)[†]</u>	<u>0.68 (0.52 to 0.87)[‡]</u>
<u>Fully adjusted[§]</u>	<u>0.62 (0.47 to 0.81)[¶]</u>	<u>0.27 (0.12 to 0.61)^{**}</u>	<u>0.69 (0.52 to 0.93)^{††}</u>
<u>Recurrent stroke</u>			
<u>Age- and sex-adjusted</u>	<u>0.71 (0.48 to 1.05)</u>	<u>0.62 (0.32 to 1.20)</u>	<u>0.76 (0.46 to 1.26)</u>
<u>Fully adjusted[§]</u>	<u>0.72 (0.46 to 1.13)</u>	<u>0.54 (0.27 to 1.08)</u>	<u>0.88 (0.48 to 1.61)</u>
<u>Myocardial infarction</u>			
<u>Age- and sex-adjusted</u>	<u>0.72 (0.39 to 1.33)</u>	<u>0.25 (0.05 to 1.31)</u>	<u>0.89 (0.45 to 1.78)</u>
<u>Fully adjusted^{¶¶}</u>	<u>0.72 (0.36 to 1.44)</u>	<u>NC</u>	<u>NC</u>

* 442 cases included in analyses of entire follow-up period

[†]p-value <0.001

[‡]p-value 0.003

[§]Analyses of entire follow-up period and 1 year onwards adjusted for age, sex, atrial fibrillation, prior ischaemic heart disease, prior cardiac failure and smoking; analyses for 0-1 year period adjusted for age, sex, atrial fibrillation and prior ischaemic heart disease (unable to incorporate additional covariates due to small number of outcomes)

[¶]P-value 0.001

^{**}p-value 0.002

^{††}p-value 0.02

^{¶¶}Adjusted for age, sex, atrial fibrillation and history of ischaemic heart disease (unable to incorporate additional covariates due to small number of outcomes)

HR = hazard ratio; CI: confidence interval; HR: NC = not calculated (too few outcomes to adjusted for additional covariates)